Who will win the Covid19 vaccine race?

0
157
IMAGE SOURCE: GETTY IMAGES

I bought this stock, Novavax (NASDAQ:NVAX) earlier this year before it blew up and I wish, that I was a richer man who could have bought 1000’s of shares. I would have made alot of money, but I actually think this stock isn’t finished gaining value.

I might even buy a couple more shares of Novavax when I have the money to do so.

When it comes to the Covid19 virus and vaccines in development and production, I think Novavax will end up being the biggest winner. I will refer to Motley Fool’s Taylor Carmichael and his article, which shows that Novavax are miles ahead of the other leading vaccine candidates.

(From Motley Fools article)
In June, OWS (Operation Warpspeed) narrowed its favorite vaccine candidates down to five companies: Moderna (NASDAQ:MRNA)Merck (NYSE:MRK)Pfizer (NYSE:PFE)Johnson & Johnson (NYSE:JNJ), and AstraZeneca (NYSE:AZN). But in July, OWS shocked the world by instead granting $1.6 billion in funding to tiny Novavax.

The decision to send $1.6 billion to Novavax was not made simply because Novavax is a small company. And it was not made just because management has friendly relations with CEPI.

The simplest explanation is probably the best one. The federal government really wants a working COVID-19 vaccine. This is why it’s granting such high dollar amounts in the first place. And science doesn’t play favorites. Novavax was selected for a $1.6 billion grant not because it’s a small company or enjoys favoritism. Novavax won that grant because its animal data is the most promising of all the vaccine candidates to date.

Back in June, Novavax announced its animal data for its vaccine candidate, NVX-CoV2373.  “We are seeing neutralizing titers in the 10,000 range in nonhuman primates,” said Dr. Gregory Glenn, the head of research and development at Novavax. Other companies are reporting antibody data in the 40 to 200 range in animal testing.

As a point of contrast, earlier this month Pfizer and its partner, BioNTech (NASDAQ:BNTX), announced that in a phase 1 trial, 10 micrograms of its vaccine candidate produced an average of 168 antibodies in humans, while a dose of 30 micrograms yielded 267.

LEAVE A REPLY

Please enter your comment!
Please enter your name here